TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31054101

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (RT) - 30 Gy in 6 fractions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chemotherapy (CHT) - temozolomide 200 mg/m2/day for 5 days every 28 days
Number of subjects: 31
Study: 29222362

Group type: EXPERIMENTAL
Intervention: Intervention units with revised policy allowing pen storage in locking boxes and education provided to nurses
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control units with no change in policy
Number of subjects: 8
Study: 25826322

Group type: EXPERIMENTAL
Intervention: RGN‐259 (0.1%) eye drops, 6 times daily for 28 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 9
Study: 23952850

Group type: EXPERIMENTAL
Intervention: Lung cancer screening with chest radiography and computer-aided detection
Number of subjects: 1424

Group type: EXPERIMENTAL
Intervention: Notification of the presence of a lung nodule
Number of subjects: 1424
Study: 21422759

Group type: EXPERIMENTAL
Intervention: Human tissue kallikrein with conventional treatment over 12-14 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study: 19386771

Group type: EXPERIMENTAL
Intervention: ATHENA intervention (coach-led peer-facilitated sessions during sport season)
Number of subjects: 1668
Study: 17684876

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg plus Droperidol 1.25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg plus Dexamethasone 8 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 15228025

Group type: EXPERIMENTAL
Intervention: Vacutex dressing (capillary action dressing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment by wound area and description
Number of subjects: 0
Study: 12361440

Group type: EXPERIMENTAL
Intervention: Duct tape occlusion (applied directly to the wart for a maximum of 2 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cryotherapy (liquid nitrogen applied to each wart for 10 seconds every 2-3 weeks for a maximum of 6 treatments)
Number of subjects: 61
Study: 10381673

Group type: EXPERIMENTAL
Intervention: sICAM‐1 serum levels in patients with intermediate uveitis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: sICAM‐1 and IL-8 levels in intermediate uveitis patients
Number of subjects: 61
Study: 8562742

Group type: EXPERIMENTAL
Intervention: Zaldaride maleate (20 mg four times per day)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg followed by 2 mg after each unformed stool)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Zaldaride maleate
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 2205641

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 6159902

Group type: EXPERIMENTAL
Intervention: Indanazoline E-VA-16
Number of subjects: 35

Group type: COMPARATOR
Intervention: Xylometazoline
Number of subjects: 35
Study: 6502494

Group type: EXPERIMENTAL
Intervention: Oral milrinone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 39
Study: 30238650

Group type: EXPERIMENTAL
Intervention: Self-management intervention using teach-back, including individual teaching session, heart failure booklet, weighing scales, diary for daily weight, follow-up phone call 2 weeks after discharge.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual education plus heart failure booklet (control group).
Number of subjects: 140
Study: 28036350

Group type: EXPERIMENTAL
Intervention: 2.8MM probe‐CMA test
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMA testing
Number of subjects: 0
Study: 25446376

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sorafenib (1000 mg/m2 once weekly for 7 weeks + 1 week rest, then once every 3 weeks + 1 week rest)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sorafenib
Number of subjects: 102

Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Hand-foot syndrome (HFS)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Absence of PDGFRβ expression
Number of subjects: 102
Study: 22440125

Group type: EXPERIMENTAL
Intervention: Decrease in urinary albumin excretion (UAE) of 2 logs at 1 year
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Increase in urinary albumin excretion (UAE) of 2 logs at 1 year
Number of subjects: 393
Study: 20237316

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously and 75 mg of aspirin orally once daily along with intense pregnancy surveillance
Number of subjects: 294

Group type: COMPARATOR
Intervention: Intense pregnancy surveillance alone
Number of subjects: 294
Study: 18617121

Group type: EXPERIMENTAL
Intervention: Triple nerve stimulation (radial, median, and musculocutaneous nerves)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radial plus musculocutaneous nerve stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triple nerve stimulation
Number of subjects: 60
Study: 15809570

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Percent time spent in moderate to vigorous physical activity (MVPA)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Time spent in light‐intensity physical activity
Number of subjects: 394
Study: 12888186

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (6.6 g/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10588554

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study: 8577018

Group type: EXPERIMENTAL
Intervention: Zinc acetate at low pH (AL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc acetate at high pH (AH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc oxide at low pH (OL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc oxide at high pH (OH)
Number of subjects: 10
Study: 2012087

Group type: EXPERIMENTAL
Intervention: Cholestyramine powder (8 g, twice daily)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cholestyramine bar (8 g, twice daily)
Number of subjects: 83
Study: 6187322

Group type: EXPERIMENTAL
Intervention: Endocrine manipulation
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 168
Study: 31910877

Group type: EXPERIMENTAL
Intervention: EBMeDS system (intervention group)
Number of subjects: 3815

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3815
Study: 31373112

Group type: EXPERIMENTAL
Intervention: Topical Citrullus colocynthis oil, applied two times per day for 2 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo, applied two times per day for 2 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Topical Citrullus colocynthis oil
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 28093029

Group type: EXPERIMENTAL
Intervention: 7.5 mg mirtazapine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 50 mg quetiapine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 27143858

Group type: EXPERIMENTAL
Intervention: Low sodium diet (50 mEq/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High sodium diet (300 mEq/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg
Number of subjects: 16
Study: 25159241

Group type: EXPERIMENTAL
Intervention: Direct peritoneal resuscitation (DPR) with peritoneal lavage using 2.5% DELFLEX
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Direct peritoneal resuscitation (DPR)
Number of subjects: 88
Study: 22306735

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with peripheral stem cell rescue
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hormone receptor-positive disease
Number of subjects: 98
Study: 19581636

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 337

Group type: COMPARATOR
Intervention: Conventional staging
Number of subjects: 337
Study: 17763111

Group type: EXPERIMENTAL
Intervention: Active bupropion and active 4‐mg gum (AA)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Active bupropion and placebo gum (AP)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo bupropion and placebo gum (PP)
Number of subjects: 608
Study: 14768921

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (n = 18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% (n = 18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (Ropivacaine 0.2% and Bupivacaine 0.125%)
Number of subjects: 40
Study: 11598360

Group type: EXPERIMENTAL
Intervention: Depot medroxy progesterone acetate (DMPA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no hormonal pre‐medication)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 50
Study: 9740160

Group type: EXPERIMENTAL
Intervention: Biocompatible hemodialysis membranes (BCMs)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Bioincompatible hemodialysis membranes (BICM)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Oliguria at onset of dialysis
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: APACHE II score with BCMs in nonoliguric patients
Number of subjects: 153
Study: 7804477

Group type: EXPERIMENTAL
Intervention: Cholestyramine with psyllium hydrophilic mucilloid (PHM) 5.1 g twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cholestyramine therapy (4 g twice daily)
Number of subjects: 27
Study: 3049118

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of atenolol and nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (individual components)
Number of subjects: 0
Study: 31898914

Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle or use of statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31094804

Group type: EXPERIMENTAL
Intervention: Catheter inserted at the proximal subparaneural location (n = 31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Catheter inserted at the distal supraparaneural location (n = 32)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both interventions (proximal and distal)
Number of subjects: 63
Study: 27131979

Group type: EXPERIMENTAL
Intervention: Modified auriculotherapy (different points ear puncture with xylocaine without needles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 25545026

Group type: EXPERIMENTAL
Intervention: Oral fingolimod 0.5mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral fingolimod 1.25mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular interferon β‐1a (IFNβ‐1a IM) 30 μg/mL once weekly
Number of subjects: 0
Study: 23988084

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 22146674

Group type: EXPERIMENTAL
Intervention: Hydrogen-enriched water (1.0 liter per day for 12 weeks) in open-label trial
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hydrogen-enriched water (0.5 liter per day for 8 weeks) in double-blind trial
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo water in double-blind trial
Number of subjects: 36
Study: 19248104

Group type: EXPERIMENTAL
Intervention: 0.9% MQX-503 gel
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219

Group type: COMPARATOR
Intervention: MQX-503 and Placebo
Number of subjects: 219
Study: 17087689

Group type: EXPERIMENTAL
Intervention: Occupational/Physical Therapy (OT/PT) intervention delivered via teletechnology or in-home visits
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Traditional home setting OT/PT sessions (trad group n = 16)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Remote OT/PT sessions via teletechnology (tele group n = 16)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 65
Study: 15672958

Group type: EXPERIMENTAL
Intervention: GnRH antagonist ganirelix
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH agonist leuprolide acetate
Number of subjects: 0
Study: 11397620

Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg qd
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg bid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ofloxacin 400 mg bid
Number of subjects: 10
Study: 9310602

Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg/kg daily) plus weekly Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Iron supplementation plus weekly placebo
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Weekly Deltaprim (malaria prophylaxis)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Malaria chemoprophylaxis
Number of subjects: 832
Study: 8378244

Group type: EXPERIMENTAL
Intervention: Remoxipride oral suspension (100 mg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain solution (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsule (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remoxipride oral suspension
Number of subjects: 0
Study: 3544660

Group type: EXPERIMENTAL
Intervention: Lysine‐vasopressin (LVP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glypressin
Number of subjects: 50
Study: 30951785

Group type: EXPERIMENTAL
Intervention: Chitosan-bioglass complex (CB)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Chitosan-bioglass slurry (CBS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard remineralisation solution (RS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Deionised water (NC)
Number of subjects: 64
Study: 29587801

Group type: EXPERIMENTAL
Intervention: Dangguixu-san (DS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25629790

Group type: EXPERIMENTAL
Intervention: linagliptin 5mg once daily
Number of subjects: 154

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 154
Study: 24664172

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g orally each day for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22466551

Group type: EXPERIMENTAL
Intervention: LTG monotherapy
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: LTG+VPA
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: LTG+PHT
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: LTG+PB
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: LTG+CBZ
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: LTG+inducers
Number of subjects: 621
Study: 19752279

Group type: EXPERIMENTAL
Intervention: AHM (Anti-Hantaan virus monoclonal antibody) at doses of 2.5 to 20 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: AHM (Anti-Hantaan virus monoclonal antibody)
Number of subjects: 88
Study: 17290062

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual supportive care
Number of subjects: 288
Study: 15386328

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (benign breast tumours)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with oestrogen receptor-negative tumours
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with poorly differentiated tumours
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with more advanced primary tumour stage
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with involved lymph nodes
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with distant metastases
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with more advanced TNM stage
Number of subjects: 64
Study: 11286848

Group type: EXPERIMENTAL
Intervention: Arm 2 (with simultaneous IM‐MS irradiation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Arm 1 (without simultaneous IM‐MS irradiation)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Optimal IM‐MS irradiation
Number of subjects: 32
Study: 7974045

Group type: EXPERIMENTAL
Intervention: Breast-milk and premature formula (550 mg calcium and 300 mg phosphorus)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Breast-milk only
Number of subjects: 53
Study: 2493710

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.2 mg intravenously, followed by increments of 0.1 mg at 60 s intervals until eye opening
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam 0.2 mg/kg, vecuronium bromide 0.1 mg/kg intravenously, and 3 vol.% isoflurane in oxygen for induction; nitrous oxide 66% in oxygen and 0.9 vol.% isoflurane for maintenance
Number of subjects: 40
Study: 30394344

Group type: EXPERIMENTAL
Intervention: 400 μg of rectal misoprostol before cesarean section
Number of subjects: 120

Group type: COMPARATOR
Intervention: 400 μg of rectal misoprostol after cesarean section
Number of subjects: 120
Study: 27044318

Group type: EXPERIMENTAL
Intervention: Flapless approach with enamel matrix derivative (EMD) proteins
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minimally invasive surgery (MIST) with enamel matrix derivative (EMD) proteins
Number of subjects: 30
Study: 25708866

Group type: EXPERIMENTAL
Intervention: niacin 6000 mg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 22739330

Group type: EXPERIMENTAL
Intervention: EX-WBV (exercise with whole-body vibration)
Number of subjects: 32

Group type: COMPARATOR
Intervention: EX (exercise without whole-body vibration)
Number of subjects: 32
Study: 21321039

Group type: EXPERIMENTAL
Intervention: Immediate abduction treatment (6 weeks)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Active sonographic surveillance
Number of subjects: 128
Study: 19922671

Group type: EXPERIMENTAL
Intervention: Insulin Resistance (IR) assessed by HOMA-IR
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1168
Study: 16958567

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day MPH administered in five different paradigms
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12612308

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Asthmatic subjects)
Number of subjects: 24
Study: 10690818

Group type: EXPERIMENTAL
Intervention: Sclerocorneal tunnel incision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clear corneal tunnel incision
Number of subjects: 100
Study: 9146851

Group type: EXPERIMENTAL
Intervention: Transdermal delivery of acetylcholine via iontophoresis (150 microA for 40 s) at various sites in the forearm and hand
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Baseline microcirculation flow recorded by laser Doppler fluxmetry (LDF)
Number of subjects: 13
Study: 8180458

Group type: EXPERIMENTAL
Intervention: T2-weighted fast spin-echo (FSE) imaging
Number of subjects: 100

Group type: COMPARATOR
Intervention: T2-weighted conventional spin-echo (CSE) imaging
Number of subjects: 100
Study: 2834115

Group type: EXPERIMENTAL
Intervention: Heparin pretreatment (5000 IU IV before exercise)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 10
Study: 31302075

Group type: EXPERIMENTAL
Intervention: Percutaneous acetic acid injection (PAAI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PAAI
Number of subjects: 55

Group type: COMPARATOR
Intervention: RFA
Number of subjects: 55
Study: 30450368

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training (MIAT) for 12 weeks, 50 min, 3 days per week, at 60% of maximal HR
Number of subjects: 24
Study: 27664548

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT) with 12 sessions, two involving family members
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 98
Study: 26025792

Group type: EXPERIMENTAL
Intervention: Vitamin B12 ointment for 2 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study: 23374199

Group type: EXPERIMENTAL
Intervention: Strain-counterstrain treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Strain-counterstrain treatment after full osteopathic treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham treatment after full osteopathic treatment
Number of subjects: 61
Study: 21675956

Group type: EXPERIMENTAL
Intervention: Gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18481716

Group type: EXPERIMENTAL
Intervention: Jiaji point group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Reinforcing kidney and strengthening spleen point group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 90